Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Receptor agonist activity

HT1A Receptor Affinity Agonistic Receptor Activity ... [Pg.613]

Table 4.3 Agonists, receptors activated and principal effects produced. Table 4.3 Agonists, receptors activated and principal effects produced.
NMD A receptors are selectively activated by A/-methyl-D-aspartate (NMD A) (182). NMD A receptor activation also requires glycine or other co-agonist occupation of an allosteric site. NMDAR-1, -2A, -2B, -2C, and -2D are the five NMD A receptor subunits known. Two forms of NMDAR-1 are generated by alternative splicing. NMDAR-1 proteins form homomeric ionotropic receptors in expression systems and may do so m situ in the CNS. Functional responses, however, are markedly augmented by co-expression of a NMDAR-2 and NMDAR-1 subunits. The kinetic and pharmacological properties of the NMD A receptor are influenced by the particular subunit composition. [Pg.551]

The ability of receptors to couple to G-proteins and initiate GTPase activity may also be independent of ligand. Thus, specific mutations in a- and P-adrenergic receptors have led to receptors that mediate agonist-independent activation of adenylyl cyclase (69,70). These mutations presumably mimic the conformational state of the ligand-activated receptor when they are activated conventionally by ligands. [Pg.279]

FIGURE 2.11 Receptor-occupancy curves for activation of human calcitonin type 2 receptors by the agonist human calcitonin. Ordinates (response as a fraction of the maximal response to human calcitonin). Abscissae (fractional receptor occupancy by human calcitonin). Curves shown for receptors transfected into three cell types human embryonic kidney cells (HEK), Chinese hamster ovary cells (CHO), and Xenopus laevis melanophores. It can be seen that the different cell types lead to differing amplification factors for the conversion from agonist receptor occupancy to tissue response. [Pg.27]

The most probable mechanism for inverse agonism is the same one operable for positive agonism namely, selective receptor state affinity. However, unlike agonists that have a selectively higher affinity for the receptor active state (to induce G-protein activation and subsequent physiological response) inverse agonists have a selectively higher affinity for the inactive receptor state and thus uncouple already spontaneously coupled [RaG] species in the system. [Pg.49]

While the extended ternary complex model accounts for the presence of constitutive receptor activity in the absence of ligands, it is thermodynamically incomplete from the standpoint of the interaction of receptor and G-protein species. Specifically, it must be possible from a thermodynamic point of view for the inactive state receptor (ligand bound and unbound) to interact with G-proteins. The cubic ternary complex model accommodates this possibility [23-25]. From a practical point of view, it allows for the potential of receptors (whether unbound or bound by inverse agonists) to sequester G-proteins into a nonsignaling state. [Pg.50]

FIGURE 3.12 Dependence of constitutive receptor activity as ordinates (expressed as a percent of the maximal response to a full agonist for each receptor) versus magnitude of receptor expression (expressed as the amount of human cDNA used for transient transfection, logarithmic scale) in Xenopus laevis melanophores. Data shown for human chemokine CCR5 receptors (open circles), chemokine CXCR receptors (filled triangles), neuropeptide Y type 1 receptors (filled diamonds), neuropeptide Y type 2 receptors (open squares), and neuropeptide Y type 4 receptors (open inverted triangles). Data recalculated and redrawn from [27],... [Pg.52]

The first idea to consider is the effect of receptor density on sensitivity of a functional system to agonists. Clearly, if quanta of stimulus are delivered to the stimulus-response mechanism of a cell per activated receptor the amount of the total stimulus will be directly proportional to the number of receptors activated. Figure 5.8 shows Gi-protein-mediated responses of melanophores transiently transfected with cDNA for human neuropeptide Y-l receptors. As can be seen from this figure, increasing receptor expression (transfection with increasing concentrations of receptor cDNA) causes an increased potency and maximal response to the neuropeptide Y agonist PYY. [Pg.85]


See other pages where Receptor agonist activity is mentioned: [Pg.137]    [Pg.139]    [Pg.249]    [Pg.4]    [Pg.279]    [Pg.137]    [Pg.139]    [Pg.249]    [Pg.4]    [Pg.279]    [Pg.139]    [Pg.140]    [Pg.220]    [Pg.517]    [Pg.380]    [Pg.205]    [Pg.206]    [Pg.9]    [Pg.10]    [Pg.21]    [Pg.24]    [Pg.27]    [Pg.45]    [Pg.49]    [Pg.80]    [Pg.85]    [Pg.88]    [Pg.90]    [Pg.108]    [Pg.115]    [Pg.122]    [Pg.133]    [Pg.138]    [Pg.156]    [Pg.179]    [Pg.183]    [Pg.183]    [Pg.204]    [Pg.206]    [Pg.208]    [Pg.211]    [Pg.212]    [Pg.212]    [Pg.212]    [Pg.212]    [Pg.214]   
See also in sourсe #XX -- [ Pg.109 ]




SEARCH



5-Receptor agonists pharmacological activity

Active receptor

Agonist receptor activation

Agonist receptor activation

Agonistic activity

Constitutively Active Receptors and Inverse Agonists

K-Receptor agonists pharmacological activity

P-Receptor agonists pharmacological activity

Peroxisome Proliferator-Activated Receptor y-Agonists and Stroke

Peroxisome proliferator activated receptor -a agonists

Peroxisome proliferator-activated receptor 7 agonists

Peroxisome proliferator-activated receptor PPAR agonists)

Peroxisome proliferator-activated receptor PPARy) agonists

Peroxisome proliferator-activated receptor agonists thiazolidinediones

Peroxisome proliferator-activated receptor-y agonists

Peroxisome proliferator-activated receptors dual agonists

Peroxisome proliferators activator receptor PPAR) agonists

Receptor activation

Receptor activity

Receptor agonists

Receptor agonists/activators

Structure-activity relationships of dopamine receptor agonists

Test Systems Addressing 5-HT4 Receptor Agonist Activity

The Distinction between Agonist Binding and Receptor Activation

The del Castillo-Katz Mechanism 1. Relationship between Agonist Concentration and Fraction of Receptors in an Active Form

© 2024 chempedia.info